StockWatch
·
NATCO PHARMA LTD. · QQ2 FY-2027 · THE CALL

Lenalidomide erosion, Semglutide headwinds outweigh pipeline optimism

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsNATCOPHARMNATCO PHARMA LTD.18 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade C

FY27 PAT upgraded from 700-750 Cr to 'less than 800 Cr,' but hedged language ('probably'). No revenue guidance offered vs prior 3,400-3,500 Cr. H1 PAT (₹400 Cr) suggests ~₹650-700 Cr annualized unless strong H2 recovery—below raised target.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

NATCO faces near-term margin and revenue headwinds: Lenalidomide competition eroding ₹200+ Cr revenue base, Semglutide market share capped at 5-6% with zero profitability in sight, PAT down 61% despite management's cautious optimism. FY27 PAT guidance raised to ~₹800 Cr (from 700-750 Cr) but H1 performance (₹400 Cr aggregate) leaves little buffer. Mid-term upside from Carfilzomib exclusivity, Brazil momentum, and CHS demerger (mid-2027) post-2027, but execution risks high and profitability recovery timing uncertain.

₹967.3 Cr

Revenue · −29% YoY

₹202.6 Cr

Reported PAT · −60.9% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

International formulation business strong driver of QoQ growth

OVERSTATED

QoQ revenue +31.6% but YoY -29%; international growth offset by Lenalidomide collapse

Brazil business 66% growth highly encouraging

MET

Brazil revenue ₹121 Cr (66% growth confirmed), but represents only ~12.5% of Q2 revenue; small base

Domestic base business improved with 20% bump, sustainable

Partial

Domestic ₹145 Cr reported; prior guidance ₹100-110 Cr suggests growth, but management cites Semglutide stocking as one-time factor; sustainability unclear

EBITDA margin at 30.4% sustainable

OVERSTATED

NPM 19.9% with OPM 26.7%; EBITDA 30.4% but PAT conversion weak, suggesting tax/interest headwinds or one-offs

FY27 PAT guidance 700-750 Cr on track

OVERSTATED

Management now says 'probably less than ₹800 Cr' (upgraded), but admits Q1 weak, Q2 weak, expecting Q3-Q4 recovery; annualized from H1 alone would miss prior guidance

Earnings quality

What changed since the last call

Deltas vs. the prior call

FY27 PAT guidance raised

Upgrade

Prior 700-750 Cr, now management signaling 'probably less than ₹800 Cr' (+50-100 Cr midpoint raise). But H1 actual ₹400 Cr leaves limited buffer for 800+ Cr run rate.

FY27 revenue guidance withdrawn

Withdrawn

Prior 3,400-3,500 Cr (but Q1 annualized to 2,940 Cr). Management now avoids committing, says 'closer to end of year' for clarity. Implies downward revision expected.

Domestic business momentum upgraded

Upgrade

Q2 ₹145 Cr vs prior ₹100-110 Cr run rate; +35-45% beat. Management cites Semglutide stocking and growth, but admits stocking is one-time factor; base runs ₹130-135 Cr.

Semglutide profitability timeline pushed out

Downgrade

Prior calls implied 'interesting opportunity.' Now management admits 'no profits coming in near future, maybe in long run.' Signals margin pressure & competitive intensity not previously disclosed.

Adcock acquisition stake raised to 49%

New

Increased from 36% in Sept 2026 to 49% by July 2026 (after rights issue close). Demerger estimated mid-year 2027 (pushed 4-6 months from original plan due to capital structure recertification).

The Q&A

Analysts pressed hard on Semglutide market share (Ruchi Sethia: 'pricing has been really bad'), Pomalidomide first-to-file claim (Shekhar Jain: exclusive status confusion), Adcock CEO strategy (Aman Hasan: acquisition path), and acquisition Price-to-Earnings (Digvijay Patil: 'how big'). Management held steady on most but was defensive on profitability timelines, ceding Semglutide as 'unprofitable near-term' and declining to quantify carfilzomib exclusivity value. Analysts sensed margin erosion; management acknowledged it only obliquely.

The exchanges that mattered

Pomalidomide first-to-file — Shekhar Jain, Individual Investor

Answered

Shared first-to-file among 5-6 generics. 180-day exclusivity ended; price erosion steep. Impact not material to earnings given competition.

Rights issue use of proceeds — Shekhar Jain, Individual Investor

Partial

Primarily to reduce Adcock-linked debt; some reserved for working capital and acquisition exploration (no specific target disclosed).

Semglutide market share — Ruchi Sethia, Analyst

Answered

Estimated 5-6% volume, 3% value share. Pricing collapsed ('not been great'). Profitability 'long run, maybe'—no near-term profit expected.

Domestic business sustainability — Kunal Randeria, Analyst

Partial

Semglutide stocking in H1; core domestic runs ₹130-135 Cr base. Good momentum but stocking is one-time; sustainable run-rate lower.

R&D spend predictability — Abdul Kedar, Analyst

Partial

R&D unpredictable quarter-to-quarter based on program milestones. FY27 expected ₹300-350 Cr (8-10% of sales); Q3-Q4 may moderate. CHS demerger filing fees also spike spending.

Carfilzomib exclusivity strategy — Shekhar Jain, Analyst

Answered

60 mg filed first; 30 mg & 10 mg approved much later so others could file. Regulatory race; first wins exclusivity. 60 mg has shared FTF (~2 generics), lower strengths competed.

FY27 guidance reaffirmation — Rashmi Shetty, Analyst

Dodged

Management now signals 'probably less than ₹800 Cr' (raised), not ₹700-750 Cr. Q3-Q4 expected stronger. For now, 'we can do better' and target ₹775-800 Cr.

FY28 outlook and growth rate — Gagan Thareja, Analyst

Partial

Expect 10-15% ROW growth. Base business growth 15-20% internal target. But won't quantify margin expansion; depends on launch execution and acquisition success.

Acquisition price and PE multiples — Digvijay Patil, Analyst

Dodged

Looking for 'value for money.' Already spent ₹3,500 Cr on acquisitions (last 4-5 years). Will evaluate Adcock path and other options. No hurry. No specific PE target disclosed.

Para IV pipeline and Ozempic (Semaglutide) landscape — Rahul Chaudhary, Analyst

Partial

Settlement with innovator done; exclusivity confirmed and FDA approval received in 30 months. For ROW, strategy unclear; regulatory queries pending.

Guidance

Forward guidance and management's confidence

FY27 10-15% growth (ROW), no India guidance offered

Medium

Management deferred FY27 consolidated revenue target, says 'closer to year-end for clarity.' Prior was 3,400-3,500 Cr (Q1 annualized to 2,940 Cr). Current trajectory suggests 2,900-3,000 Cr possible.

No OPM/NPM guidance; EBITDA 30%+ maintained in base

Low

EBITDA margin maintained at 30.4% but NPM compression from prior years evident (19.9% now vs historical ~20-22%). Semglutide unprofitable drag expected to persist.

FY27 capex ~₹400 Cr (target ~₹350-400 Cr annually)

High

H1 capex ₹300+ Cr already deployed (API facilities, formulation upgrades, oncology line setup). Management reaffirmed ₹400 Cr annual run-rate ongoing for capacity expansions.

Risks the call surfaced

Ranked by how much they should concern a holder

Lenalidomide revenue erosion

High

Lenalidomide experienced 'shared first-to-file' among 5-6 competitors post-180-day exclusivity. Price erosion 'quite steep.' India market size declining as off-patent penetration stabilizes. Revenue cliff estimated ₹200+ Cr YoY loss.

Semglutide pricing collapse

High

Semglutide pricing has 'been really bad' per analyst feedback. NATCO holds 5-6% volume, 3% value share. Profitability 'coming in the near future? No.' Domestic ₹145 Cr includes ₹130-135 Cr Semglutide run rate; unprofitable contribution dragging consolidated PAT.

CHS demerger execution risk

High

Crop Health Sciences (agri-chemical business) experiencing margins pressure (₹20 Cr EBITDA loss expected FY27). Demerger timeline pushed from 'by-year-end' to 'mid-year 2027' due to capital structure recertification and SEBI/NCLT approvals. Delay extends pre-spin losses and creates uncertainty for valuation.

Adcock Ingram integration risk

Medium

NATCO increased stake from 36% to 49% in Adcock Ingram (July 2026). South Africa-based company facing 'one-time charge' in Q2 earnings (layoffs due to non-profit product line shutdown). Flu season peaks Q1 (high profit), Q2 lower. Regulatory approvals for Adcock portfolio expansion take 2-3 years. Integration complexity high.

Acquisition strategy vagueness

Medium

Management states they are 'shopping for different transactions' with ₹2,250 Cr net cash post-rights issue, but no specific target disclosed. No target PE multiples, deal size, or timeline. Prior 4-5 years spent ₹3,500 Cr on acquisitions; ROI uncertain for Adcock and others. Strategy appears reactive rather than proactive.

Management

Score 6/10. Management (Rajeev Nannapaneni, VC & CEO) articulate but evasive on key metrics. Acknowledged lumpy earnings, margin pressure, and competitive challenges. Reluctant to quantify FY27-28 guidance, preferring to 'wait closer to year-end for clarity.' Some transparency on Semglutide profitability ('no profits near-term') but hedging on acquisition strategy and Para IV timelines. Track record mixed: prior FY27 PAT guidance 700-750 Cr raised to ~800 Cr (upgrade), but H1 actual ₹400 Cr leaves tight H2 targets. FY27 revenue guidance withdrawn (prior 3,400-3,500 Cr) implying downward revision. Adcock integration ongoing; CHS demerger delayed 4-6 months. Capex guidance stable (₹400 Cr/year) but execution on launches (Carfilzomib, Trabectedin) pending regulatory approval.

What to watch next
  • 1 · Q3 FY27 (Oct-Dec 2026)

    Carfilzomib (60 mg) launch; first-to-file exclusivity expected to ramp

  • 2 · Q4 FY27 (Jan-Mar 2027)

    Trabectedin and Olaparib launches pending regulatory approval; multiple specialty oncology products

  • 3 · CY 2027 mid-year

    CHS demerger expected post SEBI/NCLT approvals; unlocks standalone NATCO valuation

Mid-term upside from Carfilzomib exclusivity, Brazil momentum, and CHS demerger (mid-2027) post-2027, but execution risks high and profitability recovery timing uncertain.

Informational and educational content only. Not investment advice.